Viral And Host Factors That Determine The Outcome Of Stoppage Of Drugs In Chronic Hepatitis B e Ag Negative Patients.
Not Applicable
Completed
- Conditions
- Health Condition 1: B181- Chronic viral hepatitis B withoutdelta-agent
- Registration Number
- CTRI/2021/09/036468
- Lead Sponsor
- ational Health Mission
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1 Adult Patients( Age 18-65 Years) with e Antigen Negative Chronic Hepatitis B
2 Continuous Tenofovir or Entecavir Monotherapy for at least 2 Years
3 HBV DNA <250 Copies/ml at The Time of Enrollment
4 Sustained Viral Suppression ( at Least 3 Report of HBV DNA at 6 Months Interval Showing Undetectable Viral Load)
Exclusion Criteria
1 Patients with significant fibrosis ( Fibroscan >8 Kpa LSM or Liver Biopsy or USG Abdomen shows Cirrhosis, APRI >1.5, FIB4 >3.25
2 Immunocompromised
3 HCC
4 Pregnancy
5 Co-Infection
6 Patient Who Received Dual Antivirals or PEG INF
7 Patients on Lamivudine or Adefovir
8 Patient not Willing to Participate in the Study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method